Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/61879
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis |
Autor: | Mollinedo, Faustino CSIC ORCID ; Gajate, Consuelo CSIC ORCID ; Canto-Jañez, Esther del; Rivas-Elena, Juan V. | Fecha de publicación: | 2009 | Editor: | American Society for Pharmacology and Experimental Therapeutics | Citación: | Journal of Pharmacology and Experimental Therapeutics 329(2): 439-449 (2009) | Resumen: | Edelfosine (1-O-octadecyl-2-0-methyl-rac-glycero-3-phos-phocholine; ET-18-OCH3) is an antitumor alkyl-lysophospho-lipid analog that binds lipid rafts, altering their protein composition (J Exp Med 200:353-365). Because L-selectin locates in lipid rafts and plays a crucial role in the recruitment of leukocytes into inflamed tissues, we hypothesized that edelfosine might affect inflammation by modulating L-selectin and inflammatory cell migration. Here, we have found that edelfosine inhibited neutrophil-endothelium interaction through L-selectin shedding. Oral treatment of edelfosine diminished inflammation in two murine animal models. Edelfosine showed a higher antiinflammatory effect than the nonsteroidal anti-inflammatory drug (NSAID) indomethacin in the bentonite mouse-paw edema model. Using a rat model of experimental colitis, edelfosine oral administration ameliorated the clinical and histopathologic severity of the inflammatory colitis with a dramatic decrease in mucosal damage and neutrophil infiltration. Colon sections from edelfosine-treated rats showed a remarkable reduction in ulcer formation, edema, and inflammatory cell infiltration. Edelfosine enhanced lipopolysaccharide- induced expression of anti-inflammatory interleukin-10 in mouse macrophages. Edelfosine oral treatment in rats, at doses 8-fold higher than those displaying anti-inflammatory action, lacked toxicity. Edelfosine treatment showed no any significant car-diotoxicity, hepatotoxicity or renal toxicity. Unlike NSAIDs, edelfosine did not inhibit prostaglandin E2 synthesis in gastrointestinal mucosal biopsies, and no histologic alteration in gastrointestinal tract was detected after drug treatment. Thus, edelfosine shows a potent in vitro and in vivo anti-inflammatory activity while sparing gastric mucosa. Our data identify edelfosine as a novel anti-inflammatory drug by abating neutrophil infiltration through L-selectin shedding and may provide a new therapeutic approach for inflammatory bowel disease free from toxicity. Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics. | URI: | http://hdl.handle.net/10261/61879 | DOI: | 10.1124/jpet.108.148254 | Identificadores: | doi: 10.1124/jpet.108.148254 issn: 0022-3565 e-issn: 1521-0103 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
33
checked on 20-abr-2024
WEB OF SCIENCETM
Citations
34
checked on 28-feb-2024
Page view(s)
297
checked on 24-abr-2024
Download(s)
115
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.